Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Naloxone for Binge Eating Disorder
NCT01567670Phase 3Unknown
- Sponsor
- Opiant Pharmaceuticals
- Start
- Aug 2011
- Primary completion
- Jun 2012
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of naloxone in binge eating disorder (BED), sponsored by Opiant Pharmaceuticals. Status: unknown.
02
Drugs
naloxone
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT01567670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567670.